References
- AgrasWSPharmacotherapy of bulimia nervosa and binge eating disorder: longer-term outcomesPsychopharmacol Bull19973343369550889
- American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders19954Washington, DCAmerican Psychiatric Association
- BrambillaFAetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatmentCNS Drugs2001151193611460890
- CarterWPHudsonJILalondeJKPharmacologic treatment of binge eating disorderInt J Eat Disord200334S74S8812900988
- ClercGMilnacipran/Fluvoxamine Study groupAntidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamineInt Clin Psychopharmacol20011614551
- El-GiamalNde ZwaanMBailerUReboxetine in the treatment of bulimia nervosa: a report of seven casesInt Clin Psychopharmacol200015351611110011
- El-GiamalNde ZwaanMBailerUMilnacipran in the treatment of bulimia nervosa: a report of 16 casesEur Neuropsychopharmacol20031373912650949
- FairburnCGHarrisonPJEating disordersLancet20033614071612573387
- FassinoSDagaGABoggioSUse of reboxetine in bulimia nervosa: a pilot studyJ Psychopharmacol200418423815358988
- FichterMMKrugerRRiefWFluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathologyJ Clin Psychopharmacol1996169188834413
- FirstMBSpitzerRLGibbonMStructured Clinical Interview for DSM-IV axis 1 Disorders. Patient edition1997New YorkBiometric Research, New York State Psychiatric Institute SCID-I/P, version 2.0
- FukuchiTKanemotoKDifferential effects of milnacipran and fluvoxamine, especially in patients with severe depression and agitated depression: a case-control studyInt Clin Psychopharmacol20021753811890186
- HamiltonMThe assessment of anxiety states by ratingBr J Med Psychol19593250513638508
- HamiltonMA rating scale for depressionJ Neurol Neurosurg Psychiatry196923566214399272
- HazenEFavaMSuccessful treatment with duloxetine in a case of treatment refractory bulimia nervosa: a case reportJ Psychopharmacol200620723416401659
- HendersonMFreemanCPA self-rating scale for bulimia, the ‘BITE’Br J Psychiatry198715018243651670
- JimersonDCLesemMDKayeWHLow serotonin and dopamine metabolite concentrations in cerebrospinal fluid from bulimic patients with frequent binge episodesArch Gen Psychiatry19924913281372494
- Lopez-IborJGuelfiJDPletanYMilnacipran and selective serotonin reuptake inhibitors in major depressionInt Clin Psychopharmacol199611suppl 44168923126
- MalhotraSKingKHWelgeJAVenlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patientsJ Clin Psychiatry200263802612363121
- MilanoWPetrellaCSabatinoCTreatment of bulimia nervosa with sertraline: a randomized controlled trialAdv Ther200421232715605617
- NakaiYHamagakiSTakagiRThe validity of Bulimic Investigatory Test, Edinburgh (BITE) and the survey of bulimia nervosaSeishin igaku19984071116
- National Institute of Mental HealthGuyWClinical Global ImpressionsECDEU Assessment Manual for Psychopharmacology1976Revised EdRockville, MDNIMH21722
- RomanoSJHalmiKASarkarNPA placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatmentAm J Psychiatry20021599610211772696
- TauscherJPirkerWWilleitM[123I]β-CTI and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosaBiol Psychiatry2001493263211239903